SHS sells shares phenox GmbH, a leading manufacturer of instruments and implants for the treatment of stroke

A successful exit

25-Apr-2022 - Germany

The Tübingen-based healthcare investor SHS, which together with NRW Bank invested growth capital in the medical technology manufacturer phenox GmbH, sells its shares to the cooperation partner Wallaby Medical.


The fast-growing MedTech company phenox specialises in instruments and implants for the neurointerventional therapy of stroke

The fast-growing Bochum-based company was founded in 2005 with the aim of developing innovative technologies and solutions for the treatment of neurovascular diseases. phenox products are used in the treatment of ischaemic and haemorrhagic stroke. phenox has become a market leader in this field due to innovative products and groundbreaking technologies and is now one of the three market leaders in Europe. The buyer, Wallaby Medical, based in Laguna, California and Shanghai, China, is already a cooperation partner of phenox with joint market development in the USA and China. Together, the development of key markets in Europe, but also China and Japan, is now to be intensified.

“We are pleased to have been able to support phenox GmbH on its very successful way. It was a pleasure to work with the experienced and highly competent team led by founder and CEO Prof. Dr. Monstadt. We are sure that phenox, together with Wallaby, will continue its fast growth in other regions beyond Europe. We wish phenox and its employees all the best on their way to worldwide growth,” says the founder of the Tübingen-based healthcare investor SHS and former advisory board member of phenox, Dr. Bernhard Schirmers.

“We are very grateful for the support of SHS. Last but not least, we were also able to benefit from the fact that SHS, as an industry investor, has an international medical technology network and holds a portfolio that offers synergies,” explains phenox CEO Prof. Dr.-Ing. Monstadt.

“The investment in phenox is a great example from our portfolio that high innovative strength and management competence combined with growth capital and the network of a medtech investor can be extremely successful ” notes SHS partner Dr André Zimmermann.

SHS invested from the third SHS fund generation and an SHS parallel fund refinanced by KfW. In the 2022, this is the 2nd exit for the SHS third fund generation with a very attractive return.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.